The study investigates the potential of lutetium texaphyrin (MLu) as a photocatalyst for triggering pyroptosis, a form of inflammatory cell death, through biomolecular photoredox catalysis. MLu, a near-infrared (NIR) photocatalyst, is found to efficiently oxidize biomolecules such as NADH, NADPH, and various amino acids, leading to pyroptosis via the caspase 3/GSDME pathway. This mechanism is distinct from its role as a photodynamic therapy sensitizer. The study also explores two analogs of MLu, gadolinium texaphyrin (MGd) and manganese texaphyrin (MMn), which are ineffective as photocatalysts or ROS generators. MLu's ability to induce pyroptosis at low concentrations and its effectiveness in both 2D and 3D breast cancer models suggest its potential as a novel therapeutic agent for cancer immunotherapy. The findings highlight the importance of biomolecular photoredox catalysis in photo-controlled pyroptosis activation (PhotoPyro) and its potential for developing next-generation cancer treatments.The study investigates the potential of lutetium texaphyrin (MLu) as a photocatalyst for triggering pyroptosis, a form of inflammatory cell death, through biomolecular photoredox catalysis. MLu, a near-infrared (NIR) photocatalyst, is found to efficiently oxidize biomolecules such as NADH, NADPH, and various amino acids, leading to pyroptosis via the caspase 3/GSDME pathway. This mechanism is distinct from its role as a photodynamic therapy sensitizer. The study also explores two analogs of MLu, gadolinium texaphyrin (MGd) and manganese texaphyrin (MMn), which are ineffective as photocatalysts or ROS generators. MLu's ability to induce pyroptosis at low concentrations and its effectiveness in both 2D and 3D breast cancer models suggest its potential as a novel therapeutic agent for cancer immunotherapy. The findings highlight the importance of biomolecular photoredox catalysis in photo-controlled pyroptosis activation (PhotoPyro) and its potential for developing next-generation cancer treatments.